SG11202005701VA - Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists - Google Patents
Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonistsInfo
- Publication number
- SG11202005701VA SG11202005701VA SG11202005701VA SG11202005701VA SG11202005701VA SG 11202005701V A SG11202005701V A SG 11202005701VA SG 11202005701V A SG11202005701V A SG 11202005701VA SG 11202005701V A SG11202005701V A SG 11202005701VA SG 11202005701V A SG11202005701V A SG 11202005701VA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazole
- cyclohexyl acids
- linked
- lpa antagonists
- carbamoyl cyclohexyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762607541P | 2017-12-19 | 2017-12-19 | |
PCT/US2018/066110 WO2019126085A1 (en) | 2017-12-19 | 2018-12-18 | Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202005701VA true SG11202005701VA (en) | 2020-07-29 |
Family
ID=65003575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202005701VA SG11202005701VA (en) | 2017-12-19 | 2018-12-18 | Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
Country Status (13)
Country | Link |
---|---|
US (1) | US11384067B2 (en) |
EP (1) | EP3728216B1 (en) |
JP (1) | JP7301839B2 (en) |
CN (1) | CN111699180A (en) |
AU (1) | AU2018388482A1 (en) |
BR (1) | BR112020011953A2 (en) |
CA (1) | CA3085347A1 (en) |
EA (1) | EA202091500A1 (en) |
ES (1) | ES2962367T3 (en) |
IL (1) | IL275361A (en) |
MX (1) | MX2020005874A (en) |
SG (1) | SG11202005701VA (en) |
WO (1) | WO2019126085A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR108838A1 (en) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | CARBAMOYLOXIMETHYL ACID TRIAZOL CYCLOHEXILO AS LPA ANTAGONISTS |
US11447475B2 (en) * | 2017-12-19 | 2022-09-20 | Bristol-Myers Squibb Company | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
US20210317131A1 (en) * | 2018-09-18 | 2021-10-14 | Bristol-Myers Squibb Company | Oxabicyclo acids as lpa antagonists |
CN111434655A (en) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | Lysophosphatidic acid receptor antagonists and process for their preparation |
WO2021097039A1 (en) | 2019-11-15 | 2021-05-20 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
TWI838626B (en) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa receptor antagonists and uses thereof |
JP2023529369A (en) | 2020-06-03 | 2023-07-10 | ギリアード サイエンシーズ, インコーポレイテッド | LPA receptor antagonists and their uses |
WO2022174882A1 (en) * | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
CA3218917A1 (en) * | 2021-05-11 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
AR128613A1 (en) | 2022-02-25 | 2024-05-29 | Lhotse Bio Inc | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH THE ACTIVITY OF THE LPA RECEPTOR |
CN117024409A (en) * | 2023-10-10 | 2023-11-10 | 药康众拓(北京)医药科技有限公司 | Deuterated LPA1 inhibitor compounds and uses thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60234318D1 (en) | 2001-02-08 | 2009-12-24 | Ono Pharmaceutical Co | FOR THE TREATMENT OF RESPIRATORY DISEASES, COMPRISING MEANS FOR THE CONTROL OF THE LPA RECEPTOR |
US7432271B2 (en) * | 2003-09-02 | 2008-10-07 | Bristol-Myers Squibb Company | Pyrazolyl inhibitors of 15-lipoxygenase |
DE102004038403B4 (en) | 2004-08-07 | 2006-08-31 | Sanofi-Aventis Deutschland Gmbh | Process for preparing the enantiomeric forms of cis-configured 3-hydroxycyclohexanecarboxylic acid derivatives |
JP2013501064A (en) | 2009-08-04 | 2013-01-10 | アミラ ファーマシューティカルス,インコーポレーテッド | Compounds as lysophosphatidic acid receptor antagonists |
GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
US9272990B2 (en) | 2010-12-07 | 2016-03-01 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis |
US8785442B2 (en) | 2011-01-30 | 2014-07-22 | Curegenix, Inc. | Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof |
WO2012138648A1 (en) | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
WO2013085824A1 (en) | 2011-12-04 | 2013-06-13 | Angion Biomedica Corp. | Small molecule anti-fibrotic compounds and uses thereof |
CA2869564A1 (en) | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | N-aryltriazole compounds as lpar antagonists |
AU2013279510A1 (en) | 2012-06-20 | 2014-10-16 | F. Hoffmann-La Roche Ag | Substituted pyrazole compounds as LPAR antagonists |
CN104411692A (en) | 2012-06-20 | 2015-03-11 | 霍夫曼-拉罗奇有限公司 | N-alkyltriazole compounds as lpar antagonists |
AU2014232383B2 (en) * | 2013-03-15 | 2019-01-17 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
WO2016044556A2 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
AR108838A1 (en) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | CARBAMOYLOXIMETHYL ACID TRIAZOL CYCLOHEXILO AS LPA ANTAGONISTS |
HRP20211918T8 (en) | 2017-12-19 | 2022-04-15 | Bristol-Myers Squibb Company | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
WO2019126084A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists |
WO2019126098A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists |
EP3727589B1 (en) | 2017-12-19 | 2022-06-29 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azoles as lpa antagonists |
-
2018
- 2018-12-18 JP JP2020533674A patent/JP7301839B2/en active Active
- 2018-12-18 WO PCT/US2018/066110 patent/WO2019126085A1/en unknown
- 2018-12-18 CN CN201880089037.2A patent/CN111699180A/en active Pending
- 2018-12-18 AU AU2018388482A patent/AU2018388482A1/en not_active Abandoned
- 2018-12-18 MX MX2020005874A patent/MX2020005874A/en unknown
- 2018-12-18 US US16/954,310 patent/US11384067B2/en active Active
- 2018-12-18 BR BR112020011953-9A patent/BR112020011953A2/en not_active Application Discontinuation
- 2018-12-18 EP EP18830676.5A patent/EP3728216B1/en active Active
- 2018-12-18 EA EA202091500A patent/EA202091500A1/en unknown
- 2018-12-18 CA CA3085347A patent/CA3085347A1/en not_active Abandoned
- 2018-12-18 SG SG11202005701VA patent/SG11202005701VA/en unknown
- 2018-12-18 ES ES18830676T patent/ES2962367T3/en active Active
-
2020
- 2020-06-14 IL IL275361A patent/IL275361A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2021507895A (en) | 2021-02-25 |
CN111699180A (en) | 2020-09-22 |
EP3728216A1 (en) | 2020-10-28 |
AU2018388482A1 (en) | 2020-07-30 |
EP3728216B1 (en) | 2023-09-06 |
EA202091500A1 (en) | 2020-09-14 |
US20210087173A1 (en) | 2021-03-25 |
MX2020005874A (en) | 2020-08-13 |
CA3085347A1 (en) | 2019-06-27 |
US11384067B2 (en) | 2022-07-12 |
IL275361A (en) | 2020-07-30 |
BR112020011953A2 (en) | 2020-11-17 |
JP7301839B2 (en) | 2023-07-03 |
WO2019126085A1 (en) | 2019-06-27 |
KR20200100712A (en) | 2020-08-26 |
ES2962367T3 (en) | 2024-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL275348A (en) | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists | |
IL275361A (en) | Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists | |
ZA201808580B (en) | Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists | |
IL275346A (en) | Cyclohexyl acid triazole azines as lpa antagonists | |
IL275363A (en) | Cyclohexyl acid triazole azoles as lpa antagonists | |
EP3240839A4 (en) | White inks | |
EP3265522A4 (en) | White inks | |
IL254476A0 (en) | Heterocyclylmethyl-thienouracile as antagonists of the adenosine-a2b-receptor | |
EP3265520A4 (en) | White inks | |
PL3436539T3 (en) | Aqueous bonding composition | |
EP3119844A4 (en) | White ink | |
PL3107391T3 (en) | Fungicidal compositions of pyrazolecarboxylic acid alkoxyamides | |
HUE040612T2 (en) | Fungicidal compositions of pyrazolecarboxylic acid alkoxyamides | |
PL3245198T3 (en) | Pyrrolidine derivatives as angiotensin ii type 2 antagonists | |
HK1248557A1 (en) | Myocyte differentiation-promoting composition containing amino acids | |
RS65156B1 (en) | Emulsions comprising silicic acid | |
EP3294819A4 (en) | White inks | |
IL253147A0 (en) | Pyrazole compounds | |
EP3487840A4 (en) | Cyclohexyl benzamide compounds | |
EP3709967C0 (en) | Demake-up micellar milk | |
ZA201704292B (en) | Pyrazole compounds | |
EP3397058A4 (en) | Fungal control of white mold |